AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078). Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialise petrelintide, Zealand Pharma's amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Physical fitness and increasing muscle strength could reduce the mortality rate for cancer patients by between 31% to 46%, new research from Edith Cowan University (ECU) has found.

Around 20 million new cancer cases were reported in 2022, with 9.7 million cancer deaths reported world-wide during the same period, with experts expecting the trend to increase in the coming decades.

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalisation if they stop taking heart failure medications. This is according to a new study from Karolinska Institutet published in the top-ranked journal Circulation.

"Our finding raises awareness about the importance of implementing and not withdrawing medical treatments in daily clinical practice even if patients with heart failure experience an improvement in symptoms and pump function," says the study's last author Gianluigi Savarese,

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered - which could help drug delivery in cancer treatment.

In a paper published in PNAS, researchers at King's College London and the University of Washington describe the unique 3D structure of this protein, which is now being used to develop cancer drug delivery systems that can target drugs to tumour sites.

The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health. When this microbial balance is disturbed, it can contribute to the development of chronic diseases like ulcerative colitis (UC), an inflammatory condition of the large intestine. For some patients, current treatments offer limited relief or carry significant risks, including immune suppression. Researchers are now exploring alternative ways to restore gut health, focusing on the microbiome’s ability to heal the intestinal lining.

Bayer and Hurdle have published groundbreaking research that represents a great advancement in aging research. The research introduces and validates a novel saliva-based DNA methylation biomarker designed to quantify systemic chronic inflammation (SCI), that the researchers have named, InflammAge. This innovative approach provides a non-invasive method for quantifying and tracking inflammation-related epigenetic biomarkers associated with aging.

A common perception is that not all alcoholic beverages are alike. Red wine, for instance, is often considered a healthier choice, with many believing its high resveratrol content - an antioxidant with anti-inflammatory properties - offers protection against cancer. Researchers from the Brown University School of Public Health and the Warren Alpert Medical School, however, have put this assumption to the test.

The herb rosemary has long been linked with memory: "There's rosemary, that's for remembrance," says Ophelia in Shakespeare's Hamlet. So it is fitting that researchers would study a compound found in rosemary and sage - carnosic acid - for its impact on Alzheimer's disease. In the disease, which is the leading cause of dementia and the sixth leading cause of death in the US, inflammation is one component that often leads to cognitive decline.

Innovative insights into the role of ferroptosis, a unique form of programmed cell death, are reshaping the landscape of disease treatment. This growing field highlights how Traditional Chinese Medicine (TCM) can effectively modulate ferroptosis, offering novel therapeutic approaches for various conditions, including cancer, cardiovascular diseases, neurodegenerative disorders, and organ injuries. The powerful bioactive compounds in TCM have demonstrated the ability to regulate iron metabolism, lipid peroxidation, and redox balance, positioning them as key players in advancing modern medicine.

The NHS could prevent thousands more heart attacks and strokes every year by offering everyone in the UK aged 50 and over a single "polypill" combining a statin and three blood pressure lowering drugs, according to academics from UCL.

In an opinion piece for The BMJ, the authors argued that a polypill programme could be a "flagship strategy" in Labour's commitment to preventing disease rather than treating sickness.

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of the drug's side effects such as nausea, constipation and significant loss of muscle mass.

The newly discovered molecule, BRP, acts through a separate but similar metabolic pathway and activates different neurons in the brain - seemingly offering a more targeted approach to body weight reduction.

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells hijack various cellular functions to find and exploit energy and other resources, including a group of enzymes that help normal cells maintain a balance of energy.

These enzymes, called creatine kinases (CK), allow cells to transport energy produced at the mitochondria to where it is needed throughout the cell.

A research team led by Prof. LIU Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. XIAO Yichuan from the Shanghai Institute of Nutrition and Health of CAS elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain.

Exploring the use of antitumor bacteria in cancer therapy dates back to the 1860s.

Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to do just that. Pyronaridine has been used to treat the mosquito-borne infectious disease for over 30 years.

The discovery is the result of a serendipitous encounter at UTEP.

LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought - with potential for new therapeutic approaches.

As part of the innate immune system, dendritic cells are in the body's first line of defense against infections. They detect pathogens and coordinate the immune response.

GSK plc (LSE/NYSE: GSK) announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).

As announced previously(1), the acquisition includes lead molecule IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve outcomes for patients with GIST.

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the bacteria after they activate an immune response. Two preclinical studies, published, Jan. 10 in Nature Microbiology, tackle the challenge of engineering bacteria that are safe for use in controlled human infection trials or as better vaccines.

Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma. Since then, many therapeutic - as opposed to preventive - cancer vaccines have been in development, but none approved. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.

New research suggests that antidepressants can accelerate cognitive decline in people with dementia. At the same time, some drugs appear to be less harmful than others, which can help doctors make better treatment decisions, according to the study published in BMC Medicine.

Antidepressants are often used to relieve symptoms such as anxiety, depression, aggressiveness, and sleep disturbances in dementia sufferers.